Comparative effectiveness of esophagectomy versus endoscopic treatment for esophageal high-grade dysplasia

Annals of Surgery

Volumn 263, Issue 4, 2016, Pages 719-726

  Hu, Yinin ^a   Puri, Varun ^b   Shami, Vanessa M ^a   Stukenborg, George J ^a   Kozower, Benjamin D ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Barrett esophagus; Cost effectiveness; Decision analysis; Esophageal high grade dysplasia; Esophagectomy; Radiofrequency ablation

Indexed keywords

ADULT; AGED; ARTICLE; COMPARATIVE EFFECTIVENESS; DISEASE COURSE; ENDOSCOPIC MUCOSAL RESECTION; ESOPHAGEAL HIGH GRADE DYSPLASIA; ESOPHAGUS DYSPLASIA; ESOPHAGUS RESECTION; GROUPS BY AGE; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MEDICARE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; SENSITIVITY ANALYSIS; BARRETT ESOPHAGUS; CATHETER ABLATION; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; ESOPHAGOSCOPY; FEMALE; MALE; MARKOV CHAIN; MIDDLE AGED; PATHOLOGY; PRECANCEROUS CONDITIONS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; CATHETER ABLATION; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; ESOPHAGECTOMY; ESOPHAGOSCOPY; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; MEDICARE; MIDDLE AGED; PRECANCEROUS CONDITIONS; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; UNITED STATES;

EID: 84950133061     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001387     Document Type: Article

References (57)

1. Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143:336-346.
2. Wright CD, Kucharczuk JC, O'Brien SM, et al. Predictors of major morbidity and mortality after esophagectomy for esophageal cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk adjustment model. J Thorac Cardiovasc Surg. 2009;137:587-595; discussion 596.
3. Deb SJ, Shen KR, Deschamps C. An analysis of esophagectomy and other techniques in the management of high-grade dysplasia of Barrett's esophagus. Dis Esophagus. 2012;25:356-366.
4. Heitmiller RF. Prophylactic esophagectomy in Barrett esophagus with high-grade dysplasia. Langenbecks Arch Surg. 2003;388:83-87.
5. Tseng EE, Wu TT, Yeo CJ, et al. Barrett's esophagus with high grade dysplasia: surgical results and long-term outcome-an update. J Gastrointest Surg. 2003;7:164-170; discussion 170-171.
6. Reed MF, Tolis GJr, Edil BH, et al. Surgical treatmentofesophageal high-grade dysplasia. Ann Thorac Surg. 2005;79:1110-1115; discussion 1110-1115.
7. Dunbar KB, Spechler SJ. The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus: a systematic review. Am J Gastroenterol. 2012;107:850-62; quiz 863.
8. Hur C, Choi SE, Rubenstein JH, et al. The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology. 2012;143:567-575.
9. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009;360:2277-2288.
10. Guarner-Argente C, Buoncristiano T, Furth EE, et al. Long-term outcomes of patients with Barrett's esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. Gastrointest Endosc. 2013;77:190-199.
11. Haidry RJ, Dunn JM, Butt MA, et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastro-enterology. 2013;145:87-95.
12. Gupta M, Iyer PG, Lutzke L, et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. Gastro-enterology. 2013;145:79-86.
13. Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1245-1255.
14. Pouw RE, Wirths K, Eisendrath P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol. 2010;8:23-29.
15. Bulsiewicz WJ, Kim HP, Dellon ES, et al. Safety and efficacy of endoscopic mucosal therapy with radiofrequency ablation for patients with neoplastic Barrett's esophagus. Clin Gastroenterol Hepatol. 2013;11:636-642.
16. Menezes A, Tierney A, Yang YX, et al. Adherence to the 2011 American Gastroenterological Association medical position statement for the diagnosis and management of Barrett's esophagus [Published online ahead of print 2014]. Dis Esophagus. 2014 [Epub ahead of print].
17. Boger PC, Turner D, Roderick P, et al. A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett's oesophagus. Aliment Pharmacol Ther. 2010;32: 1332-1342.
18. Inadomi JM, Somsouk M, Madanick RD, et al. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology. 2009;136:2101-2114. e1-6.
19. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13:397-409.
20. Murphy S, Xu J, Kochanek K. Deaths: Final Data for 2010. National Vital Statistics Rep. 2013;61.
21. Wang KK, Sampliner RE. Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008;103:788-797.
22. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17:1721-1724.
23. National Comprehensive Cancer Network. NCCN Guidelines: esophageal and esophagogastric junction cancers. 2012.
24. Headrick JR, Nichols FC 3rd, Miller DL, et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg. 2002;73:1697-1702; discussion 1702-1703.
25. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573.
26. Lapar DJ, Stukenborg GJ, Lau CL, et al. Differences in reported esophageal cancer resection outcomes between national clinical and administrative databases. J Thorac Cardiovasc Surg. 2012;144:1152-1157.
27. Dhungel B, Diggs BS, Hunter JG, et al. Patient and peri-operative predictors of morbidity and mortality after esophagectomy: American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP), 2005-2008. J Gastrointest Surg. 2010;14:1492-1501.
28. Centers for Medicare and Medicaid Services. Federal Register CMS-1601-FC. 2014.
29. Centers for Medicare and Medicaid Services. Physician Fee Schedule Search. 2014. Available at: http://www.cms.gov/apps/physician-fee-schedule/.
30. Hollenbeck BK, Dunn RL, Suskind AM, et al. Ambulatory surgery centers and outpatient procedure use among Medicare beneficiaries. Med Care. 2014;52: 926-931.
31. de Boer AG, Stalmeier PF, Sprangers MA, et al. Transhiatal vs extended transthoracic resection in oesophageal carcinoma: patients' utilities and treatment preferences. Br J Cancer. 2002;86:851-857.
32. Fisher D, Jeffreys A, Bosworth H, et al. Quality of life in patients with Barrett's esophagus undergoing surveillance. Am J Gastroenterol. 2002;97: 2193-2200.
33. Hur C, Wittenberg E, Nishioka NS, et al. Quality of life in patients with various Barrett's esophagus associated health states. Health Qual Life Outcomes. 2006;4:45.
34. Zapletal C, Heesen C, Origer J, et al. Quality of life after surgical treatment of early Barrett's cancer: a prospective comparison of the Ivor-Lewis resection versus the modified Merendino resection. World J Surg. 2014;38: 1444-1452.
35. Gerson LB, Ullah N, Hastie T, et al. Patient-derived health state utilities for gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:524-533.
36. Gordon LG, Mayne GC. Cost-effectiveness of Barrett's oesophagus screening and surveillance. Best Pract Res Clin Gastroenterol. 2013;27: 893-903.
37. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001;120:1630-1639.
38. Montgomery E, Bronner MP, Greenson JK, et al. Are ulcers a marker for invasive carcinoma in Barrett's esophagus? Data from a diagnostic variability study with clinical follow-up. Am J Gastroenterol. 2002;97:27-31.
39. Shaheen NJ, Inadomi JM, Overholt BF, et al. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut. 2004;53:1736-1744.
40. Smith DH, Gravelle H. The practice of discounting in economic evaluations of healthcare interventions. Int J Technol Assess Health Care. 2001;17: 236-243.
41. Boshier PR, Anderson O, Hanna GB. Transthoracic versus transhiatal esoph-agectomy for the treatment of esophagogastric cancer: a meta-analysis. Ann Surg. 2011;254:894-906.
42. Rossi M, Barreca M, de Bortoli N, et al. Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: a prospective study. Ann Surg. 2006;243: 58-63.
43. Dulai GS, Shekelle PG, Jensen DM, et al. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Am J Gastroenterol. 2005;100:775-783.
44. Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105:1523-1530.
45. Lim CH, Treanor D, Dixon MF, et al. Low-grade dysplasia in Barrett's esophagus has a high risk of progression. Endoscopy. 2007;39:581-587.
46. Wani S, Falk G, Hall M, et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2011;9:220-227; quiz e26.
47. Horwhat JD, Baroni D, Maydonovitch C, et al. Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data. Am J Gastroenterol. 2007;102:497-506.
48. Milind R, Attwood SE. Natural history of Barrett's esophagus. World J Gastroenterol. 2012;18:3483-3491.
49. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049-1057.
50. Alcedo J, Ferrandez A, Arenas J, et al. Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance. Dis Esophagus. 2009;22:239-248.
51. Davila ML, Hofstetter WL. Endoscopic management of Barrett's esophagus with high-grade dysplasia and early-stage esophageal adenocarcinoma. Thorac Surg Clin. 2013;23:479-489.
52. Tomizawa Y, Iyer PG, Wong Kee Song LM, et al. Safety of endoscopic mucosal resection for Barrett's esophagus. Am J Gastroenterol. 2013;108:1440-1447; quiz 1448.
53. Pech O, May A, Manner H, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastro-enterology. 2014;146; 652-660e1.
54. Collard JM. High-grade dysplasia in Barrett's esophagus. The case for esophagectomy. Chest Surg Clin N Am. 2002;12:77-92.
55. Hurmuzlu M, Aarstad HJ, Aarstad AK, et al. Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer. Dis Esophagus. 2011;24:39-47.
56. Sharaiha RZ, Freedberg DE, Abrams JA, et al. Cost-effectiveness of chemo-prevention with proton pump inhibitors in Barrett's esophagus. Dig Dis Sci. 2014;59:1222-1230.
57. Kuppusamy M, Sylvester J, Low DE. In an era of health reform: defining cost differences in current esophageal cancer management strategies and assessing the cost of complications. J Thorac Cardiovasc Surg. 2011;141:16-21.